Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]FP-GLU (N-(2-[18F]fluoropropionyl)-L-glutamate) is an experimental, preclinical fluorine-18-labeled L-glutamic acid analogue developed as a positron emission tomography (PET) imaging tracer. It was originally synthesized by researchers at the PET-CT Center of the First Affiliated Hospital, Sun Yat-Sen University, to image glutamate metabolism and transport in tumors. [18F]FP-GLU is primarily transported into cells via the Na+-dependent system XAG- (including excitatory amino acid transporters EAAT1 and EAAT3) and the Na+-independent system xc- (SLC7A11). It has demonstrated high tumor-to-background contrast in preclinical models of hepatocellular carcinoma (HCC), glioma, and lung adenocarcinoma, making it a promising diagnostic tool for assessing tumor metabolic heterogeneity and response to therapies such as proton beam therapy.
| Indication | Highest phase | Status |
|---|---|---|
| central nervous system (CNS) tumors | Preclinical | Active |
| fibroblastic sarcomas and related tumors | Preclinical | Active |
| hepatocellular carcinoma (HCC) | Preclinical | Active |
| lung adenocarcinoma (LUAD) | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: lung adenocarcinoma (LUAD)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]FP-GLU.
Work on [18F]FP-GLU? Claim this page to correct or add information. Claim this page